{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:37Z","timestamp":1789972117778,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.beem.2014.09.002","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T03:52:13Z","timestamp":1410839533000},"page":"871-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current and future treatments of osteoporosis in men"],"prefix":"10.1016","volume":"28","author":[{"given":"Jean-Marc","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.09.002_bib1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","article-title":"Osteoporosis: impact on health and economics","volume":"6","author":"Harvey","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.beem.2014.09.002_bib3","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","article-title":"Undertreatment of osteoporosis in men with hip fracture","volume":"162","author":"Kiebzak","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2014.09.002_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-007-0483-0","article-title":"The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study","volume":"19","author":"Papaioannou","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s11606-009-1031-8","article-title":"Population based fracture risk assessment and osteoporosis treatment disparities by race and gender","volume":"24","author":"Curtis","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.beem.2014.09.002_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(01)00614-7","article-title":"Epidemiology of fractures in England and Wales","volume":"29","author":"Van Staa","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.002_bib7","first-page":"3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.09.002_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.beem.2008.09.005","article-title":"Osteoporosis in men","volume":"22","author":"Kaufman","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00198-004-1686-2","article-title":"The burden of hospitalised fractures in Sweden","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ocl.2006.08.003","article-title":"Hip fracture and its consequences: differences between men and women","volume":"37","author":"Orwig","year":"2006","journal-title":"Orthop Clin North Am"},{"key":"10.1016\/j.beem.2014.09.002_bib12","series-title":"Assessment of osteoporosis at the primary health-care level","author":"Kanis","year":"2008"},{"key":"10.1016\/j.beem.2014.09.002_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bonemineral levels of US adults","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A\u00a0reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.002_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib16","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","article-title":"Towards a diagnostic and therapeutic consensus in male osteoporosis","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/PL00004177","article-title":"Do men and women fracture bones at similar bone densities?","volume":"11","author":"Selby","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12020-013-9880-7","article-title":"Osteoporosis in men: recent progress","volume":"44","author":"Adler","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2014.09.002_bib20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","article-title":"The pathogenesis of bone fragility in women and men","volume":"359","author":"Seeman","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.09.002_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.002_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","article-title":"Androgens and bone","volume":"25","author":"Vanderschueren","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.002_bib23","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1359\/jbmr.040916","article-title":"Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites","volume":"19","author":"Riggs","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1359\/jbmr.071020","article-title":"A\u00a0population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men","volume":"23","author":"Riggs","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1359\/JBMR.050916","article-title":"Effects of sex and age on bone microstructure at the ultradistal radius: a population-based non-invasive in\u00a0vivo assessment","volume":"21","author":"Khosla","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib26","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/jbmr.2003.18.10.1766","article-title":"Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging","volume":"18","author":"Duan","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00198-007-0407-z","article-title":"Biochemical assessment of bone turnover and bone fragility in men","volume":"18","author":"Szulc","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib28","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib29","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1210\/jc.2002-021691","article-title":"Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age","volume":"88","author":"Van Pottelbergh","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib30","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1210\/jc.2004-1717","article-title":"Aromatase activity and bone homeostasis in men","volume":"89","author":"Gennari","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.002_bib32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/er.2004-0013","article-title":"The decline of androgen levels in elderly men and its clinical and therapeutic implications","volume":"26","author":"Kaufman","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.002_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-007-0362-8","article-title":"Development of a nomogram for individualizing hip fracture risk in men and women","volume":"18","author":"Nguyen","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX\u2014assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib35","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Nelson","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00198-010-1218-1","article-title":"A\u00a0FRAX\u00ae model for the assessment of fracture probability in Belgium","volume":"22","author":"Johansson","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMcp0707217","article-title":"Clinical practice. Osteoporosis in men","volume":"358","author":"Ebeling","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib38","series-title":"Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","year":"2006"},{"key":"10.1016\/j.beem.2014.09.002_bib39","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib40","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib41","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1210\/jc.2002-021654","article-title":"An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men","volume":"88","author":"Drake","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib43","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib44","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.beem.2014.09.002_bib45","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib46","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib48","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib50","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.002_bib51","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib52","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effect of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib53","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug\u2013drug interactions in the management of women with osteoporosis","volume":"89","author":"Rizzoli","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.002_bib56","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2012-3048","article-title":"Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men","volume":"98","author":"Kaufman","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2013-1688","article-title":"Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenausal women","volume":"99","author":"Anderson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosizumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.beem.2014.09.002_bib59","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.002_bib60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.111.181404","article-title":"A\u00a0rate-limiting role for dickkopf-1in bone formationand the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody","volume":"338","author":"Glantschnig","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.beem.2014.09.002_bib62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","article-title":"Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders","volume":"27","author":"Nemeth","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib63","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1359\/jbmr.080518","article-title":"Older men with low serum estradiol and high serum SHBG have an increased risk of fractures","volume":"23","author":"Mellstrom","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.002_bib64","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone therapy on bone mineral density in hypogonadal men","volume":"82","author":"Behre","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib65","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2014.09.002_bib66","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2014.09.002_bib67","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.002_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-012-9630-5","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"91","author":"Rizzoli","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.002_bib69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bone.2012.11.018","article-title":"Treatment of osteoporosis in men","volume":"53","author":"Kaufman","year":"2013","journal-title":"Bone"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:49:14Z","timestamp":1761497354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1521690X14001031"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.002","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future treatments of osteoporosis in men","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}